Uney, K.Altan, F.Cetin, G.Aboubakr, M.Dik, B.Sayin, Z.Er, A.2024-04-242024-04-2420180140-77831365-2885https://doi.org/10.1111/jvp.12448https://hdl.handle.net/11468/17715The purpose of this study was to evaluate the pharmacokinetics of cefquinome (CFQ) following single intravenous (IV) or intramuscular (IM) injections of 2mg/kg body weight in red-eared slider turtles. Plasma concentrations of CFQ were determined by high-performance liquid chromatography and analyzed using noncompartmental methods. The pharmacokinetic parameters following IV injection were as follows: elimination half-life (t(1/2z)) 21.73 +/- 4.95hr, volume of distribution at steady-state (V-dss) 0.37 +/- 0.11L/kg, area under the plasma concentration-time curve (AUC(0-)) 163 +/- 32ghr(-1)ml(-1), and total body clearance (Cl-T) 12.66 +/- 2.51 mlhr(-1)kg(-1). The pharmacokinetic parameters after IM injection were as follows: peak plasma concentration (C-max) 3.94 +/- 0.84g/ml, time to peak concentration (T-max) 3hr, t(1/2z) 26.90 +/- 4.33hr, and AUC(0-) 145 +/- 48ghr(-1)ml(-1). The bioavailability after IM injection was 88%. Data suggest that CFQ has a favorable pharmacokinetic profile with a long half-life and a high bioavailability in red-eared slider turtles. Further studies are needed to establish a multiple dosage regimen and evaluate clinical efficacy.eninfo:eu-repo/semantics/closedAccessCefquinomePharmacokineticsRed-Eared Slider TurtleArticle411E40E44WOS:0004194031000072-s2.0-850400367612883321410.1111/jvp.12448Q1Q2